follicular adenocarcinoma

Summary

Summary: An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)

Top Publications

  1. ncbi Follow-up of differentiated thyroid cancer
    Furio Pacini
    Department of Endocrinology, University of Pisa, Ospedale Cisanello, Via Paradisa 2, 56124 Pisa, Italy
    Eur J Nucl Med Mol Imaging 29:S492-6. 2002
  2. ncbi [The frequency of malignant disease in cytological group of suspected cancer (ultrasound-guided fine-needle aspiration biopsy of nonpalpable thyroid nodules)]
    Edita Miseikyte-Kaubriene
    Vilniaus universiteto Onkologijos institutas
    Medicina (Kaunas) 44:189-94. 2008
  3. ncbi High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines
    Xiulong Xu
    Department of General Surgery, Rush Presbyterian St Luke s Medical Center, 1653 West Congress Parkway, Chicago, IL 60612, USA
    Cancer Res 63:4561-7. 2003
  4. pmc A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression
    Janete M Cerutti
    Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine, Federal University of Sao Paulo, Brazil
    J Clin Invest 113:1234-42. 2004
  5. ncbi Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area
    Ki Wook Chung
    Research Institute and Hospital, National Cancer Centre, Goyang, Gyeonggi, Korea
    Clin Endocrinol (Oxf) 65:660-6. 2006
  6. ncbi Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas
    Linda Cheung
    Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
    J Clin Endocrinol Metab 88:354-7. 2003
  7. ncbi Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application
    E Saggiorato
    Section of Endocrinology, Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, 10043 Orbassano TO, Italy
    Endocr Relat Cancer 12:305-17. 2005
  8. pmc Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification
    Rebecca E Schweppe
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine and University of Colorado Cancer Center, Denver, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 93:4331-41. 2008
  9. ncbi Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium
    Nicole Yeager
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 68:444-9. 2008
  10. ncbi Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions
    Antonio D Saiz
    Department of Pathology, Los Angeles County USC Medical Center, 2011 Zonal Avenue, Los Angeles, CA 90093, USA
    J Pathol 198:157-62. 2002

Research Grants

Detail Information

Publications204 found, 100 shown here

  1. ncbi Follow-up of differentiated thyroid cancer
    Furio Pacini
    Department of Endocrinology, University of Pisa, Ospedale Cisanello, Via Paradisa 2, 56124 Pisa, Italy
    Eur J Nucl Med Mol Imaging 29:S492-6. 2002
    ..Using this strategy, most patients will achieve definitive cure and will have a normal quality of life...
  2. ncbi [The frequency of malignant disease in cytological group of suspected cancer (ultrasound-guided fine-needle aspiration biopsy of nonpalpable thyroid nodules)]
    Edita Miseikyte-Kaubriene
    Vilniaus universiteto Onkologijos institutas
    Medicina (Kaunas) 44:189-94. 2008
    ..Group suspicious for cancer largely involves follicular neoplasms as well as lesions with cytological features of malignancy...
  3. ncbi High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines
    Xiulong Xu
    Department of General Surgery, Rush Presbyterian St Luke s Medical Center, 1653 West Congress Parkway, Chicago, IL 60612, USA
    Cancer Res 63:4561-7. 2003
    ..These observations suggest that mutated BRAF gene may cooperate with RET/PTC to induce the oncogenesis of PTC...
  4. pmc A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression
    Janete M Cerutti
    Laboratory of Molecular Endocrinology, Division of Endocrinology, Department of Medicine, Federal University of Sao Paulo, Brazil
    J Clin Invest 113:1234-42. 2004
    ..76; 95% confidence interval, [0.59, 0.93]). A simple test based on a combination of these markers might improve preoperative diagnosis of thyroid nodules, allowing better treatment decisions and reducing long-term health costs...
  5. ncbi Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area
    Ki Wook Chung
    Research Institute and Hospital, National Cancer Centre, Goyang, Gyeonggi, Korea
    Clin Endocrinol (Oxf) 65:660-6. 2006
    ..A molecular diagnostic method is needed to reduce unnecessary surgery in this group. In Korea, most thyroid cancer is the classic papillary type and the BRAF(V600E) mutation is highly prevalent...
  6. ncbi Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas
    Linda Cheung
    Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
    J Clin Endocrinol Metab 88:354-7. 2003
    ..Our findings suggest that the PAX8-PPAR gamma fusion protein promotes differentiated follicular thyroid neoplasia, although it is not sufficient per se for carcinogenesis...
  7. ncbi Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application
    E Saggiorato
    Section of Endocrinology, Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, 10043 Orbassano TO, Italy
    Endocr Relat Cancer 12:305-17. 2005
    ..The combination of three or more markers did not substantially improve the diagnostic accuracy of the test...
  8. pmc Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification
    Rebecca E Schweppe
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine and University of Colorado Cancer Center, Denver, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 93:4331-41. 2008
    ..Cell lines derived from human cancers provide critical tools to study disease mechanisms and develop novel therapies. Recent reports indicate that up to 36% of cell lines are cross- contaminated...
  9. ncbi Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium
    Nicole Yeager
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 68:444-9. 2008
    ....
  10. ncbi Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions
    Antonio D Saiz
    Department of Pathology, Los Angeles County USC Medical Center, 2011 Zonal Avenue, Los Angeles, CA 90093, USA
    J Pathol 198:157-62. 2002
    ..It was only found when cyclin D1 was overexpressed. Because cyclin D1 normally activates E2F-1, up-regulation of cyclin D1 may lead to E2F-1 overexpression in benign and malignant thyroid lesions...
  11. ncbi Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy
    C Durante
    Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 91:2892-9. 2006
    ..The goal of this study was to estimate the cumulative activity of (131)I to be administered to patients with distant metastases from thyroid carcinoma...
  12. ncbi Specific pattern of RAS oncogene mutations in follicular thyroid tumors
    V Vasko
    Institut National de la Santé et de la Recherche Médicale U555, Faculty of Medicine, Mediterranean University, Marseille, 13385 France
    J Clin Endocrinol Metab 88:2745-52. 2003
    ..They support the implication of N2-RAS mutations in the malignant progression of thyroid follicular tumors and the assumption that some atypical adenomas are precursors of follicular carcinomas...
  13. ncbi PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues
    Ludovic Lacroix
    CNRS UMR 8125 Commissariat a l Energie Atomique, LRC29V, and Department of Clinical Biology, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Eur J Endocrinol 151:367-74. 2004
    ....
  14. ncbi A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma
    Frank Weber
    Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, 9500 Euclid Avenue, NE 50, Cleveland, Ohio 44195, USA
    J Clin Endocrinol Metab 91:3584-91. 2006
    ..For the latter process, a deregulated miRNA can orchestrate the aberrant expression of several hundred target genes...
  15. ncbi Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors
    Peng Hou
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer 113:2440-7. 2008
    ..Epigenetic silencing of the PTEN gene, a negative regulator of the PI3K/AKT pathway, also occurs in thyroid tumors, but its relationship with genetic alterations in this pathway is unclear...
  16. ncbi Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential
    Mauro Papotti
    Department of Clinical and Biological Sciences, University of Turin and St Luigi Hospital, Orbassano, Turin, Italy
    Mod Pathol 18:541-6. 2005
    ..The relationship found between the markers investigated and these nuclear changes suggests that the tumors containing them are pathogenetically linked to papillary carcinomas...
  17. ncbi Diagnosis of suspicious thyroid nodules using four protein biomarkers
    Janete M Cerutti
    Department of Neurosurgery, Johns Hopkins University Medical School, Baltimore, Maryland 21231, USA
    Clin Cancer Res 12:3311-8. 2006
    ..The goal of this study was to determine if antibody markers used alone or in combination could accurately distinguish between a wider variety of benign and malignant thyroid lesions in fixed sections and FNA samples...
  18. ncbi Mutation of the PIK3CA gene in anaplastic thyroid cancer
    Ginesa Garcia-Rostan
    Institute of Molecular Pathology and Immunology of Porto University, Porto, Portugal
    Cancer Res 65:10199-207. 2005
    ..These findings indicate that mutant PIK3CA is likely to function as an oncogene among ATC and less frequently well-differentiated thyroid carcinomas. The data also argue for a role of PIK3CA targeting in the treatment of ATC patients...
  19. ncbi Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period
    Mi Young Do
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul
    Endocr J 52:701-7. 2005
    ..Further studies of the prognostic factors and effectiveness of various treatments of these patients are needed to enhance survival...
  20. ncbi Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas
    D Vitagliano
    Dipartimento di Biologia e Patologia Cellulare e Molecolare, Facolta di Medicina, Universita di Napoli Federico II, c o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Napoli, Italy
    Oncogene 25:5467-74. 2006
    ..These findings support the notion that mutated ras oncogenes could be able to drive the formation of thyroid tumors that can progress to poorly differentiated, metastatic carcinomas...
  21. ncbi Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors
    Luciane Martins
    Department of Histology and Embryology, Institute of Biomedical Sciences, Universidade de Sao Paulo, Sao Paulo 05508 900, SP, Brazil
    J Clin Endocrinol Metab 87:4806-10. 2002
    ..Thus, the use of galectin-3 immunodetection as a molecular marker for thyroid carcinoma must be interpreted with caution, particularly in the differentiation between thyroid follicular carcinoma and follicular adenoma...
  22. ncbi Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes
    V Lazar
    Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France
    J Clin Endocrinol Metab 84:3228-34. 1999
    ....
  23. ncbi Thyroid cancer
    O Gimm
    Department of General Surgery, Martin Luther University Halle Wittenberg, Halle, Germany
    Cancer Lett 163:143-56. 2001
    ..However, our growing knowledge of genes involved in thyroidal oncogenesis may contribute to the development of more effective treatment modalities. Some preliminary data on gene therapy are quite promising...
  24. ncbi Follicular neoplasms of the thyroid: view, biases, and experiences
    Virginia A LiVolsi
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Adv Anat Pathol 11:279-87. 2004
    ..The authors present their views based on their experience with the cytologic and histologic diagnosis of these tumors and propose a scheme to assist in their classification and appropriate clinical management...
  25. pmc Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma
    Changxue Lu
    Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Room 5128, Bethesda, Maryland 20892 4264, USA
    Endocrinology 151:1929-39. 2010
    ..These in vivo findings provide new insights in understanding carcinogenesis of the human thyroid...
  26. ncbi Allelotyping of follicular thyroid carcinoma: frequent allelic losses in chromosome arms 7q, 11p, and 22q
    Y Kitamura
    Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, 1-396 Kosugi-cho, Nakahara-ku, Kawasaki 211-8533, Japan
    J Clin Endocrinol Metab 86:4268-72. 2001
    ..Frequent allelic losses of markers on chromosomes 7q, 11p, and 22q suggest locations to examine for the presence of suppressor genes associated with the development of follicular thyroid carcinoma...
  27. ncbi Y-box binding protein expression in thyroid neoplasms: its linkage with anaplastic transformation
    Yasuhiro Ito
    Department of Surgery, Kuma Hospital, Kobe, Japan
    Pathol Int 53:429-33. 2003
    ..These findings suggest that YB-1 plays a role in regulating the transcription as well as translation of genes contributing to the anaplastic transformation of thyroid carcinoma...
  28. ncbi High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors
    Yangang Wang
    Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Clin Endocrinol Metab 92:2387-90. 2007
    ..Genetic alterations in the phosphatidylinositol-3-kinase (PI3K)/Akt pathway and their role in thyroid tumor pathogenesis in Chinese people remain undefined...
  29. ncbi Immunohistochemical diagnosis of papillary thyroid carcinoma
    C C Cheung
    Department of Pathology Medicine, The Freeman Center in Endocrine Onology, Mount Sinai Hospital, University of Toronto, Toronto Canada
    Mod Pathol 14:338-42. 2001
    ..HBME-1 positivity indicates malignancy but not papillary differentiation. Only rarely are all three markers negative in PC; this panel therefore provides an objective and reproducible tool for the analysis of difficult thyroid nodules...
  30. ncbi Class distinction between follicular adenomas and follicular carcinomas of the thyroid gland on the basis of their signature expression
    Beatriz S Stolf
    Ludwig Institute for Cancer Research, Sao Paulo, Brazil
    Cancer 106:1891-900. 2006
    ..Consequently, large numbers of patients undergo unnecessary thyroidectomy...
  31. ncbi How to define follicular thyroid carcinoma?
    Kurt Werner Schmid
    Institute of Pathology, University of Essen Medical School, Member of the West German Cancer Center Essen, Essen, Germany
    Virchows Arch 448:385-93. 2006
    ....
  32. ncbi Galectin-3 is a presurgical marker of human thyroid carcinoma
    F Orlandi
    Department of Clinical and Biological Sciences, University of Turin, Orbassano, Torino, Italy
    Cancer Res 58:3015-20. 1998
    ..Hence, cytoplasmic galectin-3 staining seems to be a reliable, easy, and cheap marker for presurgical diagnosis of follicular carcinomas and an even more suitable one for papillary carcinomas...
  33. ncbi Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer
    David Goldenberg
    Division of Otolaryngology, Department of Surgery, H091, College of Medicine, The Penn State University, Hershey, Pennsylvania 17033, USA
    Thyroid 18:1165-70. 2008
    ..In the present study we examined the presence and distribution of OGF and OGFr in nonmedullary thyroid cancer, including papillary, follicular, and anaplastic, as well as thyroid tissue from patients with nonmalignant disease...
  34. ncbi Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma
    Brigitte Franc
    Department of Pathology, Ambroise Pare Hospital, Boulogne, France
    Hum Pathol 34:1092-100. 2003
    ....
  35. ncbi Classification of follicular thyroid tumors by molecular signature: results of gene profiling
    Catherine B Barden
    Department of Surgery, New York Presbyterian Hospital and Weill Medical College of Cornell University, New York 10021, USA
    Clin Cancer Res 9:1792-800. 2003
    ....
  36. ncbi PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]
    T G Kroll
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Science 289:1357-60. 2000
    ..The experiments demonstrate an oncogenic role for PPARgamma and suggest that PAX8-PPARgamma1 may be useful in the diagnosis and treatment of thyroid carcinoma...
  37. pmc Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules
    Young Joo Park
    Departments of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    J Korean Med Sci 22:621-8. 2007
    ....
  38. ncbi Is thyroid follicular cancer in Japanese caused by a specific t(2; 3)(q13; p25) translocation generating Pax8-PPAR gamma fusion mRNA?
    Yatsuka Hibi
    Department of Endocrinology and Metabolism, Division of Molecular and Cellular Adaptation, Institution of Environmental Medicine, Nagoya University, Chikusa ku, Nagoya 466 8601, Japan
    Endocr J 51:361-6. 2004
    ..These findings are in contrast to previous reports and indicate that ethnic background may affect the translocation...
  39. ncbi Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors
    L G Puskas
    Laboratory of Functional Genomics, Biology Research Center, Hungarian Academy of Science, Szeged, Hungary
    Cell Mol Biol (Noisy-le-grand) 51:177-86. 2005
    ..It is apparent that a range of nodular thyroid tissue using large tumor sample numbers is necessary to establish robust markers for malignancy and to categorize tumors on the basis of small tumor samples...
  40. ncbi HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm
    Takahiro Mase
    Department of Surgery, Atsumi Hospital, Tahara, Aichi 441 3415, Japan
    Endocr J 50:173-7. 2003
    ..We conclude that immunohistochemical staining with HBME-1 may be useful clinically to pick out cases with a high risk of recurrence in follicular carcinoma, and that benign adenoma cases need close follow-up...
  41. pmc Genetic and biological subgroups of low-stage follicular thyroid cancer
    Christopher A French
    Division of Endocrinology, Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Pathol 162:1053-60. 2003
    ..The findings support a model in which separate genetic alterations initiate distinct pathways of oncogenesis in thyroid carcinoma subtypes...
  42. ncbi In situ hybridization and immunohistochemistry study of thyroid peroxidase expression in thyroid tumors
    C De Micco
    Laboratoire d Anatomie Pathologique, Faculte de Medecine Secteur Nord, Marseille, France
    Thyroid 10:109-15. 2000
    ..In situ hybridization showed a concomitant decrease in the corresponding TPO mRNA sequence. These changes could be due to abnormalities in the maturation of TPO mRNA leading to a different splicing variant...
  43. ncbi Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas
    M C Nascimento
    Thyroid Unit (LIM-25, Univ Sao Paulo Med School, Sao Paulo, Brazil
    Endocr Pathol 12:275-9. 2001
    ..1), p < 0.05). These results suggest that galectin-3 may potentially serve as a marker in difficult differential diagnosis cases involving Hürthle cell adenomas and Hürthle cell carcinomas...
  44. ncbi Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation
    R M Tuttle
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Endocrinol Metab 87:1737-42. 2002
    ..No measurable increase in serum VEGF levels can be detected 72 h after short-term TSH stimulation with rhTSH. We conclude that serum VEGF may serve as a clinical useful marker of residual differentiated thyroid cancer...
  45. ncbi Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma
    Masanori Yasuda
    Department of Pathology, School of Medicine, Tokai University, Bohseidai, Isehara, Kanagawa 259 1193, Japan
    Oncol Rep 14:1499-504. 2005
    ....
  46. ncbi RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma
    Marina N Nikiforova
    Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio 45267 0529, USA
    J Clin Endocrinol Metab 88:2318-26. 2003
    ..These results suggest that conventional follicular thyroid carcinomas develop through at least two distinct and virtually nonoverlapping molecular pathways initiated by either RAS point mutation or PAX8-PPAR gamma rearrangement...
  47. ncbi Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas
    Lori A Erickson
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 109:1965-71. 2007
    ..A series of 16 cutaneous metastases were analyzed from well-differentiated thyroid carcinomas to learn more about the clinicopathologic features and BRAF(V600E) mutation status...
  48. ncbi Cutaneous metastases of follicular thyroid carcinoma: a report of four cases and a review of the literature
    Timothy R Quinn
    Pathology Services, Inc, Cambridge, Massachusetts, USA
    Am J Dermatopathol 27:306-12. 2005
    ..Awareness of the varied morphologies of metastatic follicular thyroid carcinoma to the skin may prompt immunohistochemical analysis and the request for a complete clinical history, ultimately preventing misdiagnosis...
  49. ncbi HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma
    Yasuhiro Ito
    Department of Surgery, Kuma Hospital, Shimoyamate dori, Chuo Ku, Kobe 650 0011, Japan
    Anticancer Res 25:179-82. 2005
    ..HBME-1 has been recognized as a useful marker for diagnosing thyroid carcinoma. In this study, we investigated whether it has a diagnostic value for discriminating follicular carcinoma from adenoma...
  50. ncbi Analysis of P161NK4A protein expression in follicular thyroid tumors
    Tomasz Ferenc
    Department of Biology and Genetics, Medical University, Lodz
    Pol J Pathol 55:143-8. 2004
    ....
  51. pmc Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?
    F A Verburg
    Department of Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    Br J Cancer 91:200-4. 2004
    ..It is concluded that currently Tg-mRNA detection is not a useful tool in the follow-up of differentiated thyroid carcinoma, but that the concept of using RT-PCR measurements during follow-up still warrants further research...
  52. ncbi Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions
    Yael Oestreicher-Kedem
    Department of Otolaryngology Head and Neck Surgery, Beilinson Campus, Petah Tiqva, and Sackler Faculty of Medicine, Tel Aviv University, 17 Feivel Street, Tel Aviv, Israel 62995
    Head Neck 26:960-6. 2004
    ..Therefore, affected patients are referred for surgery, although only 20% will have a final diagnosis of malignancy. The aim of this study was to investigate the potential of galectin-3 as a marker of malignancy in these lesions...
  53. ncbi Handling of thyroid follicular patterned lesions
    Juan Rosai
    Italian Diagnostic Center, Via Saint Bon, 20, Milan, Italy
    Endocr Pathol 16:279-83. 2005
    ..In addition to the two conventional categories, i.e., adenoma and carcinoma, this scheme includes a group of tumors "of uncertain malignant potential."..
  54. ncbi Diagnostic role of galectin-3 in follicular thyroid tumors
    Marco Volante
    Virchows Arch 444:309-12. 2004
  55. ncbi Diagnosis of thyroid follicular carcinoma by the vascular pattern and velocimetric parameters using high resolution pulsed and power Doppler ultrasonography
    Megumi Miyakawa
    Department of Internal Medicine, Endocrine Center Toranomon Hospital, Tokyo, Japan
    Endocr J 52:207-12. 2005
    ....
  56. ncbi Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction
    Victor J Bernet
    Endocrine, Diabetes, and Metabolism Service, Walter Reed Army Medical Center, Washington, D C 20307, USA
    J Clin Endocrinol Metab 87:4792-6. 2002
    ....
  57. pmc Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy
    S P Finn
    Department of Histopathology, University of Dublin, Trinity College, Dublin, Ireland
    Virchows Arch 450:249-60. 2007
    ..Fifteen transcripts were significantly associated with FVPTC morphology. Surprisingly, these genes were associated with an extremely narrow repertoire of functions, including the major histocompatibility complex and cathepsin families...
  58. ncbi Analysis of Tg transcripts by real-time RT-PCR in the blood of thyroid cancer patients
    F Savagner
    Equipe Mixte Inserm Université 00 18, Laboratoire de Biochimie et Biologie Moleculaire, Centre Hospitalier Universitaire, F 49033 Angers cedex 01, France
    J Clin Endocrinol Metab 87:635-9. 2002
    ..The standardized, highly sensitive real-time RT-PCR technique may therefore prove useful as a complement to sTg assays, particularly for patients with recurrent thyroid cancer receiving T(4) therapy...
  59. ncbi Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas
    M Zou
    Department of Biological and Medical Research, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
    Endocrine 8:61-4. 1998
    ..We conclude that cyclin D1 overexpression may be relevant to thyroid carcinogenesis. Two mechanisms may be involved in the inactivation of pRb: one is through Rb gene mutations, and the other is by cyclin D1 overexpression...
  60. ncbi Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma
    S Hermann
    Department of Hematology, Oncology, and Tumor Immunology, , Humboldt University, Berlin-Buch, Germany
    Int J Cancer 92:805-11. 2001
    ..Consequently, the overexpressed p53 might be a correlate for dysregulation without loss of function. This, in turn, might be a reason for the good outcome of some patients with thyroid cancer...
  61. pmc Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer
    D Grammatopoulos
    Molecular Medicine Research Centre, Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK
    Mol Pathol 56:162-6. 2003
    ..This study investigated whether the detection of Tg mRNA in peripheral blood, using reverse transcriptase polymerase chain reaction (RT-PCR), is of value in the biochemical surveillance of patients with thyroid cancer...
  62. pmc Expression of cytokeratin 20 in thyroid carcinomas and peripheral blood detected by reverse transcription polymerase chain reaction
    T Weber
    Division of Molecular Diagnostics and Therapy, University of Heidelberg, Germany
    Br J Cancer 82:157-60. 2000
    ..Our results therefore strongly suggest that CK20 RT-PCR assays may improve the diagnosis of thyroid carcinoma and is able to detect circulating tumour cells in peripheral blood of thyroid carcinoma patients...
  63. ncbi Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma
    M D Ringel
    Department of Medicine, Washington Hospital Center and MedStar Research Institute, Washington, DC 20010, USA
    J Clin Endocrinol Metab 84:4037-42. 1999
    ..These data suggest that this quantitative Tg mRNA assay may be a sensitive marker of tumor recurrence or response to therapy, particularly in patients with anti-Tg antibodies...
  64. ncbi High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring
    Chandrasekhar Bal
    Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India 110029
    Int J Radiat Oncol Biol Phys 63:449-55. 2005
    ....
  65. ncbi Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer
    Peter Lind
    Department of Nuclear Medicine and Endocrinology, PET CT Center Klagenfurt, Austria
    Semin Nucl Med 36:194-205. 2006
    ..The fusion of the metabolic and morphologic information was able to increase the diagnostic accuracy, reduces pitfalls and changes therapeutic strategies in a reasonable number of patients...
  66. ncbi Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy
    Luca Giovanella
    Nuclear Medicine and Thyroid Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Clin Endocrinol (Oxf) 67:547-51. 2007
    ..Clearly, a negative Tg measurement may falsely reassure both the patient and the clinician in these cases...
  67. ncbi Diagnostic capabilities of I-131, TI-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy
    Shunji Fujie
    Department of Radiology, Okayama University Graduate School of Medicine and Dentistry, Okayama 700 8558, Japan
    Acta Med Okayama 59:99-107. 2005
    ..The specificity of the cervix for I-131 before ablation was markedly deteriorated, but it increased after ablation...
  68. ncbi Completion thyroidectomy after the unexpected diagnosis of thyroid cancer
    B Dewil
    Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Belgium
    B-ENT 1:67-72. 2005
    ....
  69. ncbi [Special surgical treatment of patients with nodular tumors of the thyroid gland against the background of diffuse toxic goiter]
    A F Romanchishen
    Vestn Khir Im I I Grek 164:21-4. 2005
    ..It was shown that the presence of nodules in the thyroid gland did not influence the nearest and distant results when using the corresponding surgical strategy...
  70. doi [Malignant goiter--thyroid cancer]
    Chr Reiners
    Klinik und Poliklinik fur Nuklearmedizin, Universitat Wurzburg
    Dtsch Med Wochenschr 133:2215-28; quiz 2229-30. 2008
  71. ncbi Does the presence of additional thyroid nodules on ultrasound alter the risk of malignancy in patients with a follicular neoplasm of the thyroid?
    Rebecca S Sippel
    Department of Surgery, University of California San Francisco, and the UCSF Comprehensive Cancer Center at Mount Zion, San Francisco, CA 94143 1674, USA
    Surgery 142:851-7; discussion 857.e1-2. 2007
    ..We sought to determine whether the presence of additional thyroid nodules on preoperative ultrasound decreased the risk of malignancy in a patient with a follicular neoplasm...
  72. ncbi [Thyroid microcarcinoma: experience and management in private clinic]
    Celso U M Friguglietti
    Cirurgia de Cabeça e Pescoço, Faculdade de Medicina, Universidade Santo Amaro, Sao Paulo, SP, Brazil
    Arq Bras Endocrinol Metabol 51:774-82. 2007
    ..The study of papillary microcarcinoma observed during the thyroidectomies in our private clinic...
  73. ncbi Follicular thyroid carcinoma: From diagnosis to treatment
    Jen Der Lin
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Department of General Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taiwan, R O C
    Endocr J 53:441-8. 2006
    ..Dedifferentiated, anti-angiogenic, or gene therapies for follicular thyroid cancer with distant metastases or anaplastic transformation comprise the principal directions in future research for this cancer...
  74. ncbi [Clinical course and treatment of patients with differentiated thyroid carcinoma diagnosed during the year 1995]
    Agnieszka Czarniecka
    Center of Oncology M Sklodowska Curie Memorial Institute, Gliwice, Poland
    Endokrynol Pol 56:758-65. 2005
    ..Cancer, 2000) was also performed in this study. We conclude that DTC therapy, currently recommended in our country, gives satisfactory results and that clinical outcome and therapeutic methods are similar both in Poland and Germany...
  75. ncbi A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers
    Maseeh Uz Zaman
    Karachi Institute of Radiotherapy and Neuclear Medicine, Jinnah Postgraduate Medical Centre
    J Pak Med Assoc 56:353-6. 2006
    ..To compare the efficacy of low (50 mCi) and high dose (100 mCi) Iodine-131 in ablation of differentiated thyroid cancer remnants...
  76. ncbi [Relapse of differentiated thyroid carcinoma in low-risk patients]
    Jolanta Krajewska
    Department of Nuclear Medicine and Endocrine Oncology, Comprehensive Cancer Center and M Sklodowska Curie Memorial Institute of Oncology, Gliwice Branch, Gliwice
    Endokrynol Pol 57:386-91. 2006
    ..The aim of the study was to analyze the impact of the routine follow up examinations for early detection of DTC recurrence in low risk DTC patients...
  77. ncbi The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer
    Robbert B T Verkooijen
    Department of Nuclear Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
    Eur J Endocrinol 155:801-6. 2006
    ..The mean period of follow-up was 10.6 +/- 4.1 years...
  78. ncbi [Follow-up of high-risk patients with differentiated thyroid cancer without persistent disease after initial therapy]
    Pedro Weslley S do Rosário
    Servico de Endocrinologia, Departamento de Tireoide, Santa Casa de Belo Horizonte, MG
    Arq Bras Endocrinol Metabol 50:909-13. 2006
    ..Recurrence after 5 years was only 1.3% in patients without apparent disease (negative US and DxWBS) and stimulated Tg <1 ng/ml. An algorithm for the follow-up of high-risk patients after initial therapy is presented in this study...
  79. ncbi Outcomes of patients with differentiated thyroid carcinoma following initial therapy
    Jacqueline Jonklaas
    Georgetown University Medical Center, Washington, DC 20007, USA
    Thyroid 16:1229-42. 2006
    ..We were unable to show any impact, positive or negative, of specific therapies in stage I patients...
  80. ncbi [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi]
    Aleksandra Kukulska
    Department of Nuclear Medicine and Endocrine Oncology Comprehensive Cancer Center and M Sklodowska Curie Memorial Institute of Oncology, Branch Gliwice, Gliwice
    Endokrynol Pol 57:374-9. 2006
    ..The aim of this study was to compare the early outcomes between two groups of patients with differentiated thyroid carcinoma (DTC) who received 60 or 100 mCi of (131)I for remnant ablation...
  81. ncbi Nuclear medicine approaches in the monitoring of thyroid cancer patients
    S Sergieva
    Department of Nuclear Medicine, Sofia Cancer Centre, Bulgaria
    J BUON 11:511-8. 2006
    ..To evaluate the role of some nuclear medicine approaches such as (99m)Tc-MIBI scan and (131)I whole-body scintigraphy (WBS) in the monitoring of patients with differentiated thyroid cancer (DTC)...
  82. ncbi [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course]
    A L Gutiérrez Cardo
    Servicio de Medicina Nuclear, Hospital Universitario Virgen del Rocio, Sevilla, Spain
    Rev Esp Med Nucl 26:138-45. 2007
    ....
  83. ncbi Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation
    B Salvatore
    Fondazione SDN, Naples Italy
    Q J Nucl Med Mol Imaging 52:2-8. 2008
    ..The results of FDG-PET/CT were compared with post-therapy (131)I whole body scan (131I-t-WBS) and Tg at short term follow up...
  84. ncbi [Thyroid carcinoma]
    Hiroshi Tamaki
    Dept of Surgery, Teikyo University School of Medicine
    Gan To Kagaku Ryoho 32:561-5. 2005
    ..In inherited medullary carcinoma (multiple endocrine neoplasia type 2), RET protooncogene analysis is the best for detecting early medullary thyroid carcinoma...
  85. ncbi Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma
    Andrea Frasoldati
    Unità Operativa di Endocrinologia, Arcispedale S Maria Nuova, Viale Umberto I 50, 42100 Reggio Emilia, Italy
    Cancer 97:90-6. 2003
    ..The follow-up of patients with differentiated thyroid carcinoma (DTC) is traditionally carried out with (131)I whole body scan ((131)I WBS) and serum thyroglobulin (Tg) measurement. Neck ultrasonography (US) is also used...
  86. ncbi [Update endocrinology: Thyroid sonography]
    P Bischof
    Innere Medizin, Spital Rorschach
    Praxis (Bern 1994) 93:695-700. 2004
    ..Clinical findings, laboratory results, ultrasonography and fine needle aspiration biopsy can be used alone or in combination, depending on the indication observed, to help find the accurate diagnosis...
  87. ncbi An aggressive approach to the surgical management of suspicious thyroid nodules
    S Al-Dbahri
    Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec
    J Otolaryngol 30:203-7. 2001
    ..We suggest that total thyroidectomy can be performed, without excessive morbidity. If performed for all suspicious thyroid nodules, it will eliminate the need for completion thyroidectomies and high ablative does of 131I...
  88. ncbi Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy?
    Georg Zettinig
    Department of Nuclear Medicine, University of Vienna, Austria
    Clin Endocrinol (Oxf) 56:377-82. 2002
    ..This study was performed (1) to analyse retrospectively patients with bone metastases from differentiated thyroid carcinoma and (2) to evaluate the impact of surgery of bone metastases on survival...
  89. ncbi Technetium-99m methoxyisobutylisonitrile imaging in the follow-up of differentiated thyroid carcinoma
    J Sriprapaporn
    Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand, 10700
    Ann Acad Med Singapore 31:195-8. 2002
    ..To evaluate the potential of technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI) imaging as an alternative to I-131 total-body scan (I-131 TBS) for the follow-up of patients with differentiated thyroid carcinoma (DTC)...
  90. ncbi Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine
    Sin Ming Chow
    Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China
    Pediatr Blood Cancer 42:176-83. 2004
    ..Differentiated thyroid carcinoma (DTC) in childhood has a good prognosis despite a high incidence of relapse. The use of radioactive iodine (RAI) has not been well established...
  91. ncbi [Primary hyperparathyroidism in patients treated for non-medullary thyroid carcinoma]
    D Rubello
    Servizio di Medicina Nucleare II, , Azienda Ospedaliera, , Padua, Italy
    Minerva Endocrinol 26:31-4. 2001
    ..Scinti-graphy using 99mTc-MIBI enabled the correct preoperative localisation of a single parathyroid adenoma in two of these patients and multiglandular pathology in the third...
  92. ncbi [Diagnosis and treatment of differentiated thyroid carcinoma]
    J Mora
    Servicio de Medicina Nuclear, Hospital de Bellvitge Hospitalet de Llobregat Barcelona
    Rev Esp Med Nucl 22:349-59; quiz 360-2. 2003
  93. ncbi Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents
    Aneeta Patel
    Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    Pediatr Res 52:737-44. 2002
    ..06). We conclude that NIS expression is associated with a lower risk of recurrence for PTC and FTC of children and adolescents...
  94. ncbi [Follow-up of children and young adults with differentiated thyroid cancer treated with radioiodine]
    M Coronado Poggio
    Servicio de Medicina Nuclear, Hospital Universitario La Paz, Madrid, Spain
    Rev Esp Med Nucl 22:316-26. 2003
    ..In our experience, the use of radioiodine is effective and safe in the follow-up of children and youngs with DTC...
  95. ncbi [Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma]
    P Gómez Camarero
    Unidad de Diagnóstico de Medicina Nuclear, Hospitales Universitarios Virgen del Rocio, Sevilla, Espana
    Rev Esp Med Nucl 22:295-305. 2003
    ..To determine the value of the use of radio-iodine scanning diagnostic and radio-iodine therapy during the follow-up of advanced differentiated thyroid cancer without stopping thyroid hormone suppression therapy...
  96. ncbi [Differentiated thyroid carcinoma. Surgery and significance of lymph node involvement]
    E Gemsenjäger
    Chirurgische Klinik, Spital Zollikerberg Neumünster, Zollikerberg Zurich, Schweiz
    Chirurg 73:38-43; discussion 43-5. 2002
    ..Nodal treatment in papillary (PTC) and in follicular (FTC) thyroid carcinoma is still a subject of debate...
  97. ncbi Differentiated thyroid carcinoma in children and adolescents. Clinical characteristics, treatment and outcome of 15 patients
    Cumhur Arici
    Department of General Surgery, Akdeniz University Medical Faculty, Antalya, Turkey
    Horm Res 57:153-6. 2002
    ..The aim of this study was to perform a retrospective analysis of treatment results for differentiated thyroid carcinoma in this age group treated in our clinic...
  98. ncbi Multifactorial analysis of survival and recurrences in differentiated thyroid cancer. Comparative evaluation of usefulness of AGES, MACIS, and risk group scores in Mexican population
    S Rodriguez-Cuevas
    Departamento de Cirugía de Cabeza, Cuello y Piel, Hospital de Oncologia, Instituto Mexicano del Seguro Social, Mexico City
    J Exp Clin Cancer Res 21:79-86. 2002
    ..In Mexican population, with 50% of high-risk patients, AGES and MACIS scores reached statistical differences with higher qualifications than observed in the U.S...
  99. ncbi Prevalence and incidence of cytoplasmic yellow bodies in thyroid neoplasms
    Harold J Rothenberg
    Division of Anatomic Pathology, Mayo Clinic, Rochester, Minn 55905, USA
    Arch Pathol Lab Med 127:715-7. 2003
    ..Cytoplasmic yellow bodies are a common and frequent histologic finding in hyalinizing trabecular adenoma of the thyroid gland, a morphologically distinctive neoplasm, and are visible in fine-needle aspiration biopsy of the tumor...
  100. ncbi Radioiodine therapy for papillary and follicular thyroid carcinoma
    Michele Klain
    Department of Nuclear Medicine and Commissariat à l Energie Atomique LRC 29V, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Eur J Nucl Med Mol Imaging 29:S479-85. 2002
    ..It should be used selectively, i.e. only in those patients for whom a clinical benefit may be expected...
  101. ncbi Expression of RET in follicular cell-derived tumors of the thyroid gland: prevalence and implication of morphological type
    Michiko Inaba
    Division of Nephrology and Metabolism, Department of Internal Medicine and Department of Pathology, Tokai University School of Medicine, Isehara, Japan
    Pathol Int 53:146-53. 2003
    ..The study found that the RET proto-oncogene is often stimulated in FCDT, not only in PTC but also in follicular tumors (FA and FTC), and may contribute to tumorigenesis of these tumors...

Research Grants9

  1. Extracellular matrix and protease markers of malignant thyroid neoplasm
    Electron Kebebew; Fiscal Year: 2007
    ..We will use these results to design a multicenter clinical trial evaluating the diagnostic and prognostic value of ECM1 and TMPRSS4 expression in patients with thyroid neoplasm. [unreadable] [unreadable] [unreadable]..
  2. Microarray analysis of thyroid neoplasm
    Martha Zeiger; Fiscal Year: 2004
    ..This will be performed using quantitative real-time RT-PCR on RNA samples from a panel of thyroid tumors. ..
  3. MODELING AND DOSIMETRY FOR RADIOLABELED ANTIBODY THERAPY
    George Sgouros; Fiscal Year: 2002
    ....
  4. STRUCTURE/FUNCTION OF GROWTH HORMONE RELATED GENE
    NORMAN EBERHARDT; Fiscal Year: 2002
    ..The chromosomal TEF-P locus will be cloned and characterized, including chromosomal localization and promoter characterization (Aim 3). ..
  5. INTRACELLULAR AMYLOIDOGENESIS AND APOPTOSIS IN NIDDM
    NORMAN EBERHARDT; Fiscal Year: 2006
    ..These studies will increase our understanding of the contribution of intracellular amyloid accumulation, induction of apoptosis, and/or interference with ER trafficking to the pathogenesis of NIDDM. ..
  6. Mentored Patient-Oriented Research Career Development Award
    Jacqueline Jonklaas; Fiscal Year: 2006
    ..A new sustained release product, which results in steady triiodothyronine levels, will furnish more physiologic replacement. This will be tested against treatment with levothyroxine, and levothyroxine and triiodothyronine. ..
  7. TUMOR SUPPRESSORS AND DIFFERENTIATED THYROID CANCER
    NORMAN EBERHARDT; Fiscal Year: 2008
    ..4) The inhibitory effects of PPFP can be modulated by PPARgamma and RXR Iigand binding. (5) PPFP alters multiple PARgamma-regulated transcription pathways, which alter growth control and/or apoptosis. ..
  8. Targeted Alpha-Particle Emitter Therapy of Metastases
    George Sgouros; Fiscal Year: 2009
    ..The work described in this application is intended to develop and evaluate such an approach. ..
  9. Molecular Classification of Suspicious Thyroid Tumors
    Martha Zeiger; Fiscal Year: 2009
    ..abstract_text> ..